Read More

Janssen Submits Application To The European Medicines Agency For RYBREVANT In Combination With Chemotherapy For The Treatment Of Adult Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer After Failure Of Prior Therapy submission is supported by data from the Phase 3 MARIPOSA-2 study featured in a Late-Breaking